<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972127</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 92579/TI/1004</org_study_id>
    <nct_id>NCT00972127</nct_id>
  </id_info>
  <brief_title>Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification Regimen</brief_title>
  <official_title>Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Open-Label, Randomized, Single Center, Multiple Dose, 2-Period, 2-Sequence, Crossover Study With and Without Application of a Urinary pH Acidification Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <brief_summary>
    <textblock>
      Primary:&#xD;
&#xD;
        -  To assess the influence of acidified urinary pH on the renal excretion of Neramexane&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  To assess the influence of acidified urinary pH on the renal excretion of N-OH&#xD;
           Neramexane&#xD;
&#xD;
        -  To assess the steady state plasma pharmacokinetics (PK) of Neramexane and N-OH&#xD;
           Neramexane under physiological conditions and under the conditions of urine&#xD;
           acidification&#xD;
&#xD;
        -  To assess safety and tolerability of a repeated dose treatment of Neramexane under&#xD;
           physiological conditions and under the conditions of urine acidification&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neramexane</intervention_name>
    <description>25 mg or 2x25mg tablets</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult subject of any ethnic origin, who is able to read, to write and fully&#xD;
             understand German language&#xD;
&#xD;
          -  Aged 18 to 45 years&#xD;
&#xD;
          -  BMI of 18-28 kg/m2 and a body weight of 50-90 kg&#xD;
&#xD;
          -  Willing and able to provide written informed consent after having been informed of the&#xD;
             requirements and the restrictions of the study&#xD;
&#xD;
          -  Female subject of childbearing potential must agree to use an effective method of&#xD;
             birth control such as sexual abstinence, vasectomised partner, non hormonal IUDs or&#xD;
             double contraception methods (e.g., condom with spermicide cream)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically relevant allergy or known hypersensitivity to&#xD;
             Neramexane/Memantine/Amantadine and their derivatives&#xD;
&#xD;
          -  History of clinically relevant allergy or known hypersensitivity to Ammonium Chloride&#xD;
&#xD;
          -  Exposure to another investigational agent within the last two months before Day 1 of&#xD;
             Period 1&#xD;
&#xD;
          -  History of clinically relevant allergy or known hypersensitivity to any inactive&#xD;
             ingredient in any of the used investigational products or tool substances&#xD;
&#xD;
          -  Lactating or pregnant female or female planning to become pregnant during study&#xD;
             conduct or within 2 months after end of study. Male planning to beget children during&#xD;
             study conduct or within 2 months after end of study&#xD;
&#xD;
          -  Any contraindications which are indicated in the topically valid SPC for Extin®N:&#xD;
             acidosis, gastritis, gastro-intestinal ulcer, hepatic or renal insufficiency,&#xD;
             hypokalemia&#xD;
&#xD;
        Lack of suitability for the trial&#xD;
&#xD;
          -  Any evidence of a significant cardiovascular, pulmonary, renal, hepatic,&#xD;
             gastrointestinal, endocrinological, metabolic (acidosis), psychiatric or other disease&#xD;
             at screening&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Any clinically relevant deviation in clinical or laboratory assessment&#xD;
&#xD;
          -  Clinically relevant abnormalities in the 12-lead ECG which in the discretion of the&#xD;
             investigator and the Merz scientific expert might affect the study objectives&#xD;
&#xD;
          -  Systolic blood pressure &lt;95 mmHg or &gt;150 mmHg or diastolic blood pressure &lt; 50 mmHg or&#xD;
             &gt;90 mmHg in supine position&#xD;
&#xD;
          -  Pulse rate &lt;45 or &gt;100 beats per minute&#xD;
&#xD;
          -  Clinically relevant chronic or acute infections&#xD;
&#xD;
          -  Acute or chronic disease, especially psychiatric or neurologic disorders&#xD;
&#xD;
          -  Current evidence of hypokalemia (= below lower limit of laboratory normal range plus&#xD;
             0.3 mmol/l as safety margin)&#xD;
&#xD;
          -  History of alcohol or drug dependence within the last 2 years&#xD;
&#xD;
          -  Alcohol consumption averaging more than 40 g for male and more than 20 g for female&#xD;
             subject daily within the last year&#xD;
&#xD;
          -  Regular caffeine consumption averaging more than 1 L of coffee and/or tea daily or&#xD;
             more than 1 L of caffeine-containing lemonades per day within the last year&#xD;
&#xD;
          -  Disorders or surgery of the gastrointestinal tract which may interfere with drug&#xD;
             absorption or may otherwise influence the pharmacokinetics of the investigational&#xD;
             medicinal products (e.g. acute inflammations, gastrointestinal disease,&#xD;
             cholecystectomy, resection of small or large intestine, etc.)&#xD;
&#xD;
          -  Use of any prescribed medication for four weeks prior to the first administration of&#xD;
             IMP.&#xD;
&#xD;
               -  Regular use of over-the-counter [OTC] drugs in the 4 weeks prior to the first&#xD;
                  administration of the IMP&#xD;
&#xD;
               -  Occasional use of OTC drugs (except paracetamol, maximum 1 g/day) within the 2&#xD;
                  weeks prior to the first administration of the IMP&#xD;
&#xD;
               -  Stable intake of thyroid hormone substitution will be allowed.&#xD;
&#xD;
          -  Use of any food, food supplement or medication known to induce or inhibit CYP3A4 or&#xD;
             other cytochrome P450 enzymes within two weeks preceding the start of the study (Day&#xD;
             1), e.g. grapefruit, St. John's wort&#xD;
&#xD;
          -  Special diet, e.g. vegetarian&#xD;
&#xD;
          -  Female subject who employed any form of hormonal contraception within 2 months prior&#xD;
             to Day 1 (e.g. oral contraceptives, hormone releasing intrauterine contraceptive&#xD;
             devices [IUDs], etc.)&#xD;
&#xD;
          -  Consume of xanthine derivates (including caffeine) within two days prior to Day 1&#xD;
&#xD;
          -  Smoker and user of snuff, nicotine replacement and chewing tobacco&#xD;
&#xD;
          -  Previous enrolment into the clinical phase of the current study&#xD;
&#xD;
          -  Positive results in any of the serology tests&#xD;
&#xD;
          -  Blood donation of more than 450 mL within 60 days prior to Day 1&#xD;
&#xD;
          -  Positive pregnancy test, if female&#xD;
&#xD;
          -  Positive drug screen or alcohol test&#xD;
&#xD;
        Administrative reasons&#xD;
&#xD;
          -  Lack of willingness or inability to co-operate adequately&#xD;
&#xD;
          -  Employee or direct relative of an employee of the CRO or Merz Pharmaceuticals GmbH&#xD;
&#xD;
          -  Lack of ability or willingness to give informed consent&#xD;
&#xD;
          -  Vulnerable subject (e.g. person kept in detention)&#xD;
&#xD;
          -  Anticipated non-availability for study visits/procedures&#xD;
&#xD;
          -  Inability to follow study procedures and investigator instructions adequately&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <last_update_submitted>February 4, 2011</last_update_submitted>
  <last_update_submitted_qc>February 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. med. Horst Jürgen Heuer</name_title>
    <organization>AAIPharma Deutschland GmbH &amp; Co. KG</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

